Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000989504 | SCV001139917 | uncertain significance | Fanconi anemia complementation group A | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001858709 | SCV002197561 | uncertain significance | Fanconi anemia | 2021-09-16 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine with valine at codon 396 of the SLX4 protein (p.Leu396Val). The leucine residue is moderately conserved and there is a small physicochemical difference between leucine and valine. This variant is not present in population databases (ExAC no frequency). This missense change has been observed in individual(s) with breast cancer (PMID: 28202063). ClinVar contains an entry for this variant (Variation ID: 803201). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |